Trial Profile
A study to evaluate the safety and efficacy of Macitentan switch from Bosentan in patients with pulmonary arterial hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2016
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2016 New trial record